Bone Marrow & Stem Cell Transplant

In the largest study of bone marrow-derived macrophages in post hematopoietic stem cell transplantation patients with a hematologic malignancy, results showed that donor derived cells from the myeloablative transplants accounted for 4.1-25% of microglial cells.

During a Targeted Oncology case-based virtual event, Jamile M. Shammo, MD, discussed testing, risk assessment, and therapy for patients with high-risk myelofibrosis.

During a live virtual event, Saad Zafar Usmani, MD, discussed 2 studies of drug combinations in patients with multiple myeloma with or without stem cell transplants.

A 51-year-old man presented with pallor and worsening fatigue on exertion.

A 51-year-old man presented with worsening fatigue on exertion and pallor with an ECOG performance score of 2 and was diagnoses with stage II standard-risk multiple myeloma.

Promising survival results were shown in the FORTE trial of carfilzomib plus lenalidomide, and dexamethasone induction/consolidation with autologous stem cell transplant and maintenance with carfilzomib-lenalidomide in patients with multiple myeloma.

Nelson J. Chao, MD, discusses a shift at Duke Cancer Institute from in-office care to home care in patients undergoing hematopoietic stem cell transplantation for hematologic malignancies.

Benefit was seen with daratumumab maintenance therapy for patients with newly diagnosed multiple myeloma who received autologous stem cell transplant plus induction and consolidation therapy with bortezomib, thalidomide, and dexamethasone.

AB-205 demonstrated robust effects and an encouraging safety profile in patients with systemic lymphoma undergoing high-dose therapy and autologous hematopoietic stem cell transplantation.